These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
977 related articles for article (PubMed ID: 33864798)
1. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Muzurović E; Mikhailidis DP; Mantzoros C Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798 [TBL] [Abstract][Full Text] [Related]
2. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Caussy C; Aubin A; Loomba R Curr Diab Rep; 2021 Mar; 21(5):15. PubMed ID: 33742318 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944 [TBL] [Abstract][Full Text] [Related]
4. Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Yang KC; Hung HF; Lu CW; Chang HH; Lee LT; Huang KC Sci Rep; 2016 Jun; 6():27034. PubMed ID: 27246655 [TBL] [Abstract][Full Text] [Related]
5. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Lee H; Kim G; Choi YJ; Huh BW; Lee BW; Kang ES; Cha BS; Lee EJ; Lee YH; Huh KB Diabetes Metab J; 2020 Apr; 44(2):267-276. PubMed ID: 30877708 [TBL] [Abstract][Full Text] [Related]
6. Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis. Bril F; Sanyal A; Cusi K Clin Liver Dis; 2023 May; 27(2):187-210. PubMed ID: 37024202 [TBL] [Abstract][Full Text] [Related]
7. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study. Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360 [TBL] [Abstract][Full Text] [Related]
8. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
9. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947 [TBL] [Abstract][Full Text] [Related]
10. NAFLD and cardiovascular diseases: a clinical review. Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080 [TBL] [Abstract][Full Text] [Related]
11. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis. Han AL BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056 [TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897 [TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease]. Kim HS; Cho YK Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101 [TBL] [Abstract][Full Text] [Related]
14. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes. Scapaticci S; D'Adamo E; Mohn A; Chiarelli F; Giannini C Front Endocrinol (Lausanne); 2021; 12():639548. PubMed ID: 33889132 [TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033 [TBL] [Abstract][Full Text] [Related]
16. Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. Katsiki N; Anagnostis P; Kotsa K; Goulis DG; Mikhailidis DP Curr Pharm Des; 2019; 25(18):2051-2059. PubMed ID: 31298151 [TBL] [Abstract][Full Text] [Related]